Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Thiogenesis Therapeutics Corp TTIPF


Primary Symbol: V.TTI

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a... see more

Recent & Breaking News (TSXV:TTI)

Thiogenesis Announces Important Core Patent Allowed in Europe

Newsfile November 4, 2024

Thiogenesis Announces Investor Relations Engagement

Newsfile September 27, 2024

Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium

Newsfile September 17, 2024

Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

Newsfile August 20, 2024

Thiogenesis Announces Leigh Syndrome Clinical Program

Newsfile July 18, 2024

Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

Newsfile March 25, 2024

Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement

Newsfile December 20, 2023

Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation

Newsfile December 18, 2023

Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium

Newsfile December 4, 2023

Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board

Newsfile November 27, 2023

Thiogenesis Announces Non-Brokered Private Placement of Common Shares

Newsfile November 20, 2023

Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update

Newsfile May 10, 2023

Thiogenesis Therapeutics (TSXV:TTI) grants stock options

Azuka Onwuka December 9, 2022

Thiogenesis Announces Stock Option Grants

Newsfile December 9, 2022

Thiogenesis Therapeutics (TSXV:TTI) closes $5.3M non-brokered private placement

John Ballem  November 21, 2022

Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement

Newsfile November 21, 2022

Thiogenesis Therapeutics (TSXV:TTI) upsizes non-brokered private placement

Azuka Onwuka November 2, 2022

Thiogenesis Announces Increase in Offering Size for Non-Brokered Private Placement of Common Shares

Newsfile November 2, 2022

Thiogenesis (TSXV:TTI) announces non-brokered private placement

Azuka Onwuka October 24, 2022

Thiogenesis Announces Non-Brokered Private Placement of Common Shares

Newsfile October 24, 2022